Danaher and GE Healthcare Face Q4 Earnings Tests After Weak Q2

Danaher and GE Healthcare Technologies will report third-quarter earnings in the coming weeks, setting the stage for a critical assessment of their operational recoveries. Both companies have experienced significant share price declines this year, with Danaher down nearly 2.7% and GE Healthcare down 16.7%, contrasting sharply with the S&P 500's 13.8% gain. Investors are now waiting to see if management teams can translate recent strategic actions into improved financial performance for the fourth quarter and beyond.

For GE Healthcare, the central question involves convincing the market that its profit margins are stabilizing. The company reported organic order growth of 11.1% in the second quarter, resulting in a book-to-bill ratio of 1.15, which suggests future revenue growth. However, margin challenges persist due to cost inflation in oil, chips, and freight. The Patient Care Solutions segment reported a loss of $26 million in the second quarter, driven by a 13.5% year-over-year decline in sales.

Management has placed the Patient Care Solutions business under strategic review, a move that often precedes disposals. To address margin issues, executives are targeting second-half improvements through higher pricing, new product introductions, and productivity actions implemented in the first half. The company maintains full-year guidance for organic revenue growth of 3% to 4%, adjusted earnings per share of $4.80 to $5.00, and adjusted EBIT margin expansion from 15.3% in 2025 to 15.4% to 15.7% in 2026.

Danaher faces a different challenge: confirming that recent shipment delays are timing issues rather than signs of continued destocking. The biotechnology segment reported only 2.5% core revenue growth in the second quarter. Outgoing CEO Rainer Blair explained that bioprocessing consumables growth fell below expectations because several large shipments for commercial customer programs moved out of the quarter.

These delays raised concerns that industry inventory levels, which were elevated following pandemic-era investments, had not yet normalized. Blair countered that current industry inventory levels are lower than in previous years. CFO Matt Gugino predicted the bioprocessing business would grow at a mid-single-digit percentage rate in the third quarter. He added that the company is likely to exit the quarter at a mid- to high single-digit growth rate as it moves forward.

For both companies, meeting existing guidance is seen as a threshold for positive market reaction. GE Healthcare's forward price-to-earnings ratio is significantly lower than its historical average, reflecting these operational setbacks. Similarly, Danaher's valuation suggests investors are pricing in significant risk regarding its bioprocessing unit. If both companies confirm their full-year targets and demonstrate progress on their specific operational hurdles, their stocks may see renewed interest from investors seeking value in the healthcare sector.